How can we boost colorectal and hepatocellular cancer screening among underserved populations?
How can we boost colorectal and hepatocellular cancer screening among underserved populations?
复制标题
DOI：
10.1007/s11894-015-0445-1
复制
发表时间：
2015-06-01
影响因子：
--
通讯作者：
Gupta, Samir
中科院分区：
文献类型：
--
作者：
Goebel, Melissa;Singal, Amit G;Gupta, Samir
结直肠癌 (CRC) 和肝细胞癌 (HCC) 是美国癌症发病率和死亡率的常见原因，特别是在服务不足的人群中，例如少数种族/族裔、保险不足/未投保以及社会经济地位较低的个人。尽管筛查可以降低癌症相关死亡率，但在服务不足的人群中，参与度并不理想，这可能是美国人群中 HCC 和 CRC 结果不平等的最大原因。在这篇叙述性综述中，我们强调了美国人群在 CRC 和 HCC 发病率和死亡率方面的不平等，并强调了潜在原因，重点关注筛查率。此外，根据最近的文献，我们强调了增加 HCC 和 CRC 筛查的有前途的策略，并提出了未来的研究和政策解决方案以优化筛查率。通过集中实施筛查策略和新颖的研究，可以减轻服务不足人群的 HCC 和 CRC 负担。
Colorectal cancer (CRC) and hepatocellular carcinoma (HCC) are common causes of cancer incidence and mortality in the USA, particularly among underserved populations such as racial/ethnic minorities, the under-/uninsured, and individuals with low socioeconomic status. Although screening can reduce cancer-related mortality, participation is suboptimal among underserved populations, likely serving as the largest contributor to observed inequities in HCC and CRC outcomes among US populations. In this narrative review, we highlight inequities across populations in the USA with respect to incidence and mortality for CRC and HCC and highlight potential causes, with a focus on screening rates. In addition, drawing from the recent literature, we highlight promising strategies for increasing screening for HCC and CRC and propose future research and policy solutions to optimize screening rates. With focused implementation of screening strategies and novel research, the burden of HCC and CRC can be reduced among underserved populations.